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Summary: 
Exploring commercialization opportunities for a machine learning algorithm that optimizes IBD therapy 
using thiopurines. I am interning for Fast Forward Medical Innovation and collaborating with Dr. Akbar 
Waljee from GI to understand the pathway of commercialization for this algorithm. Artificial intelligence is 
rapidly growing traction in healthcare and approval from the FDA making this an exciting time for us to look 
into this topic.  
 
I have completed the fastPace course through (4 weeks) for this project, conducted interviews of 
gastroenterologists, health tech entrepreneurs, administrative leaders, and insurers to understand the tasks 
that need to be addressed, and am coordinating next steps with FFMI and Dr. Waljee to help push GI 
predictive analytics into the real world.  
Methodology:  
I started by doing background research on current AI programs approved by the FDA, understanding the 
FDA requirements, SWOT analysis on predictive algorithms, background research on Dr. Waljee's algorithm, 
and customer stakeholder discovery. We are now interviewing payors and administrators to understand 
barriers to entry, implementation, and reimbursement of these technologies in the future.  
Results/Conclusion: 
The FDA is making a concerted effort to approve predictive algorithms in healthcare. About 15 technologies 
have gained approval over the past two years but the regulations governing them are rapidly evolving. 
Perhaps more importantly is how customers (ie. hospitals/providers) will actually purchase these services and 
use them. Some health systems and payers (ie. Michigan Medicine and BlueCross BlueShield) are developing 
relationships with researchers/companies to develop technologies that promote safety and value. For our GI 
project, specifically, we are now moving towards setting up a trial where we would comparing the efficacy of 
this program versus biologic use for IBD therapy.  
Reflection/Lessons Learned:  
AI is rapidly growing but has signficant limitations that the FDA, health systems, and payors are starting to 
appreciate. Making sure these algorithms actually align with all these stakeholders' values is critical for success. 
Implementation can often be more challenging than development of these algorithms. 
 
